Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells 2,771 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Christopher John Kenney sold 2,771 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $166,564.81. Following the sale, the insider directly owned 4,729 shares of the company’s stock, valued at approximately $284,260.19. This represents a 36.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Xenon Pharmaceuticals Trading Down 2.6%

Shares of NASDAQ XENE traded down $1.57 during mid-day trading on Wednesday, reaching $59.04. The company had a trading volume of 5,546,191 shares, compared to its average volume of 1,583,794. The company has a 50-day moving average price of $43.23 and a two-hundred day moving average price of $41.69. The stock has a market cap of $4.91 billion, a PE ratio of -13.54 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter last year, the business posted ($0.84) earnings per share. On average, research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC bought a new stake in Xenon Pharmaceuticals during the second quarter worth approximately $32,000. Danske Bank A S bought a new position in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Blue Trust Inc. lifted its stake in shares of Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $33,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth $39,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on XENE shares. Robert W. Baird boosted their price target on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a report on Monday. JPMorgan Chase & Co. lifted their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday. Needham & Company LLC boosted their price target on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a research note on Monday. Finally, Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $71.94.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.